Kringle Pharma First Quarter 2025 Earnings: JP¥31.13 loss per share (vs JP¥29.45 loss in 1Q 2024)

Simply Wall St

February 09, 2025

Kringle Pharma (TSE:4884) First Quarter 2025 Results

Key Financial Results

Net loss: JP¥212.0m (loss widened by 25% from 1Q 2024).
JP¥31.13 loss per share (further deteriorated from JP¥29.45 loss in 1Q 2024).

earnings-and-revenue-history — TSE:4884 Earnings and Revenue History February 9th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kringle Pharma shares are down 6.5% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Kringle Pharma has 4 warning signs (and 3 which make us uncomfortable) we think you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Kringle Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.